Nesek‐Adam 2012.
Methods | Randomised clinical trial. | |
Participants | Country: Croatia. Number randomised: 80. Post‐randomisation drop‐outs: not stated. Revised sample size: 80. Mean age: 51 years. Females: 58 (72.5%). Inclusion criteria:
Exclusion criteria:
|
|
Interventions | Participants were randomly assigned to 1 of 4 groups. Group 1: diclofenac 1 mg/kg IV 20 min before induction (n = 20). Group 2: saline 100 mL IV 20 min before induction (n = 20). Group 3: same as group 1 with ketamine IV as co‐intervention (n = 20). Group 4: same as group 2 with ketamine IV as co‐intervention (n = 20). | |
Outcomes | Drug‐related serious adverse events. | |
Notes | Attempts were made to contact authors in August 2013. | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Low risk | Quote: "Computer‐generated table of random numbers". |
Allocation concealment (selection bias) | Unclear risk | Quote: "An envelope containing group assignment was prepared, sealed, and numbered for each patient". Comment: Further details were not available. |
Blinding of participants and personnel (performance bias) All outcomes | Unclear risk | Quote: "On the morning of surgery, anesthesia technician opened the envelope and prepared completely identical syringes and infusion that were labeled "infusion" and "skin bolus" in equal volume to make the study double blind". Comment: Further details were not available. |
Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | Comment: This information was not available. |
Incomplete outcome data (attrition bias) All outcomes | Unclear risk | Comment: This information was not available. |
Selective reporting (reporting bias) | High risk | Comment: Mortality and morbidity were not reported. |
For‐profit bias | Unclear risk | Comment: This information was not available. |